Search: id:"swepub:oai:gup.ub.gu.se/297881" >
Immune infiltrate i...
-
Stenmark Tullberg, AxelGothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrenska University Hospital
(author)
Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial.
- Article/chapterEnglish2021
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/297881
-
https://gup.ub.gu.se/publication/297881URI
-
https://doi.org/10.1158/1078-0432.CCR-20-3299DOI
-
https://lup.lub.lu.se/record/0f0ec2dd-512c-4d03-ab33-5e9822e6d197URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Tumor-infiltrating immune cells play a key role in tumor progression. The purpose of this study was to analyze if the immune infiltrate predicts benefit from postoperative radiotherapy (RT) in a large randomized breast cancer RT trial.In the SweBCG91RT trial, patients with stage I and II breast cancer were randomized to breast conserving surgery (BCS) and postoperative RT or to BCS only and followed for a median time of 15.2 years. The primary tumor immune infiltrate was quantified through two independent methods; immunohistochemistry (IHC) and gene expression profiling. For IHC analyses, the absolute stromal area occupied by CD8+ T cells and FOXP3+ T cells, respectively, was used to define the immune infiltrate. For gene expression analyses, immune cells found to be prognostic in independent datasets were pooled into two groups consisting of antitumoral- and protumoral immune cells, respectively.An antitumoral immune response in the primary tumor was associated with a reduced risk of breast cancer recurrence and predicted less benefit from adjuvant RT. The interaction between RT and immune phenotype was significant for any recurrence in both the IHC and gene expression analyses (p=0.039 and p=0.035) and was also significant for IBTR in the gene expression analyses (p=0.025).Patients with an antitumoral immune infiltrate in the primary tumor have a reduced risk of any recurrence and may derive less benefit from adjuvant RT. These results may impact decisions regarding postoperative RT in early breast cancer.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Puttonen, Henri A JSahlgrenska University Hospital
(author)
-
Sjöström, Martin
(author)
-
Holmberg, Erik,1951Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrenska University Hospital(Swepub:gu)xholer
(author)
-
Chang, S LauraPFS Genomics INC
(author)
-
Feng, Felix YUniversity of California, San Francisco
(author)
-
Speers, CoreyUniversity of Michigan Health System
(author)
-
Pierce, Lori JUniversity of Michigan Health System
(author)
-
Lundstedt, Dan,1970Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrenska University Hospital(Swepub:gu)xludan
(author)
-
Killander, FredrikaLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-fki
(author)
-
Niméus, EmmaLund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Bröstcancer Proteogenomik,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Biomarkörer och Epi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast Cancer Surgery,Lund University Research Groups,Breast cancer Proteogenomics,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Biomarkers and epidemiology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-ens
(author)
-
Kovács, AnikóSahlgrenska University Hospital
(author)
-
Karlsson, Per,1963Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrenska University Hospital(Swepub:gu)xkperd
(author)
-
Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för onkologi
(creator_code:org_t)
Related titles
-
In:Clinical cancer research : an official journal of the American Association for Cancer Research27:3, s. 749-7581078-0432
Internet link
Find in a library
To the university's database
- By the author/editor
-
Stenmark Tullber ...
-
Puttonen, Henri ...
-
Sjöström, Martin
-
Holmberg, Erik, ...
-
Chang, S Laura
-
Feng, Felix Y
-
show more...
-
Speers, Corey
-
Pierce, Lori J
-
Lundstedt, Dan, ...
-
Killander, Fredr ...
-
Niméus, Emma
-
Kovács, Anikó
-
Karlsson, Per, 1 ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Clinical cancer ...
- By the university
-
University of Gothenburg
-
Lund University